Glaukos Corp (GKOS)

Glaukos Corp is a healthcare company focused on ophthalmology, developing pharmaceutical and medical technology solutions for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes iStent and iStent inject W micro-bypass stents for mild-to-moderate open-angle glaucoma, iStent infinite for glaucoma not controlled by prior therapy, and iDose TR, an intracameral therapy used to help reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also develops iLink for keratoconus, ILution for transdermal delivery of drug compounds applied to the eyelid, and a retinal XR platform targeting several posterior segment retinal diseases. Glaukos sells its products in the United States and internationally through direct sales, subsidiaries, and distributors. Founded in 1998 and headquartered in Aliso Viejo, California, the company was formerly known as Transdx, Inc.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.